Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Halozyme Therapeutics Inc’s stock clocked out at $55.64, down -0.77% from its previous closing price of $56.07. In other words, the price has decreased by -$0.77 from its previous closing price. On the day, 1.89 million shares were traded.
Ratios:
To gain a deeper understanding of HALO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.17 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.83. For the most recent quarter (mrq), Quick Ratio is recorded 7.30 and its Current Ratio is at 8.39. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 3.13.
On May 13, 2025, Leerink Partners Downgraded its rating to Underperform which previously was Market Perform but kept the price unchanged to $47.
Wells Fargo Downgraded its Overweight to Equal Weight on October 07, 2024, whereas the target price for the stock was revised from $58 to $62.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 28 ’25 when Henderson Jeffrey William sold 4,497 shares for $60.37 per share. The transaction valued at 271,467 led to the insider holds 28,611 shares of the business.
Henderson Jeffrey William sold 503 shares of HALO for $32,217 on Apr 01 ’25. The Director now owns 33,108 shares after completing the transaction at $64.05 per share. On Mar 03 ’25, another insider, Henderson Jeffrey William, who serves as the Director of the company, sold 5,000 shares for $58.69 each. As a result, the insider received 293,458 and left with 33,611 shares of the company.
Valuation Measures:
As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.76, and their Forward P/E ratio for the next fiscal year is 7.77. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.51. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.32 while its Price-to-Book (P/B) ratio in mrq is 14.21.
Stock Price History:
Over the past 52 weeks, HALO has reached a high of $70.50, while it has fallen to a 52-week low of $42.01. The 50-Day Moving Average of the stock is -6.13%, while the 200-Day Moving Average is calculated to be -1.31%.
Shares Statistics:
A total of 123.17M shares are outstanding, with a floating share count of 121.86M. Insiders hold about 1.10% of the company’s shares, while institutions hold 100.34% stake in the company.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Halozyme Therapeutics Inc (HALO).The consensus estimate for the next quarter is $1.41, with high estimates of $1.51 and low estimates of $1.18.
Analysts are recommending an EPS of between $5.63 and $4.66 for the fiscal current year, implying an average EPS of $5.32. EPS for the following year is $6.59, with 5.0 analysts recommending between $7.65 and $4.15.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $282.66M. It ranges from a high estimate of $288M to a low estimate of $278M. As of the current estimate, Halozyme Therapeutics Inc’s year-ago sales were $231.35MFor the next quarter, 6 analysts are estimating revenue of $331.47M. There is a high estimate of $348M for the next quarter, whereas the lowest estimate is $325M.
A total of 8 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $1.29B, while the lowest revenue estimate was $1.2B, resulting in an average revenue estimate of $1.24B. In the same quarter a year ago, actual revenue was $1.02BBased on 7 analysts’ estimates, the company’s revenue will be $1.48B in the next fiscal year. The high estimate is $1.59B and the low estimate is $1.22B.
